title: Reply: Considerations When Evaluating Cost-Effectiveness Analyses of Novel Stroke Prevention Therapies.
authors.forename: Vivek Y
authors.initials: VY
authors.lastname: Reddy
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Akehurst
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Amorosi
mesh_terms: D000925:Anticoagulants; D001281:Atrial Fibrillation; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years; D020521:Stroke; D014859:Warfarin
chemical_list: D000925:Anticoagulants; D014859:Warfarin